共 50 条
- [31] EVALUATION OF LIVER OUTCOMES RELATIVE TO USE OF GLP-1 RECEPTOR AGONISTS (GLP1A) AND/OR SGLT-2 INHIBITORS (SGLT2I) IN REAL-WORLD POPULATIONS DIAGNOSED WITH TYPE II DIABETES (T2DM) AND NASH/NAFLD OR AT RISK OF NASHVALUE IN HEALTH, 2020, 23 : S143 - S144Lai, M.Frick, A.Juneja, K.Koch, B.Milligan, S.Natha, M.Radtchenko, J.Younossi, Z.Afdhal, N.
- [32] Underlying mechanisms and cardioprotective effects of SGLT2i and GLP-1Ra: insights from cardiovascular magnetic resonanceCARDIOVASCULAR DIABETOLOGY, 2024, 23 (01)Cersosimo, AngelicaSalerno, NadiaSabatino, JolandaScatteia, AlessandraBisaccia, GiandomenicoDe Rosa, SalvatoreDellegrottaglie, SantoBucciarelli-Ducci, ChiaraTorella, DanieleLeo, Isabella
- [33] Underlying mechanisms and cardioprotective effects of SGLT2i and GLP-1Ra: insights from cardiovascular magnetic resonanceCardiovascular Diabetology, 23Angelica CersosimoNadia SalernoJolanda SabatinoAlessandra ScatteiaGiandomenico BisacciaSalvatore De RosaSanto DellegrottaglieChiara Bucciarelli-DucciDaniele TorellaIsabella Leo
- [34] Encouraging the prescribing of SGLT2i and GLP-1RA medications to reduce cardiovascular and renal risk in patients with type 2 diabetes: Rationale and design of a randomized controlled trialAMERICAN HEART JOURNAL, 2025, 285 : 39 - 51Haff, NancyHorn, Daniel M.Bhatkhande, GauriSung, MeekangColling, CaitlinWood, WendyRobertson, TedGaposchkin, DanielSimmons, LeighYang, JudyYeh, JamesCrum, Katherine L.Hanken, Kaitlin E.Lauffenburger, Julie C.Choudhry, Niteesh K.
- [35] Do GLP-1RA and SGLT2i Reduce Cardiovascular Mortality in African American Patients with Type 2 Diabetes? A Meta-analysisDIABETES, 2019, 68Mishriky, Basem M.Powell, James R.Wittwer, Jennifer A.Chu, Jennifer X.Sewell, KerryWu, QiangCummings, Doyle M.
- [36] GLP1RA Compared to SGLT2i Improves Depression Parameters in VeteransOBESITY, 2023, 31 : 87 - 88Jain, AradUbalde, Shannen NicoleEsper, LayalPowell, JosephMeyer, KristinSen, Sabyasachi
- [37] SGLT2i and GLP1-RA exert additive cardiorenal protection with a RAS blocker in uninephrectomized db/db miceFRONTIERS IN PHARMACOLOGY, 2024, 15Martos-Guillami, NereaVergara, AnderLlorens-Cebria, CarmenMotto, Aku EnamMartinez-Diaz, IreneGoncalves, FranciscoGarcias-Ramis, Maria MagdalenaAllo-Urzainqui, EstibalizNarvaez, AlonsoBermejo, SheilaMunoz, VicentLeon-Roman, JuanFerrer-Costa, RoserJacobs-Cacha, ConxitaVilardell-Vila, JordiSoler, Maria Jose
- [38] Risk-Benefit of SGLT2 Inhibitors (SGLT2i) vs. GLP-1 Receptor Agonists (GLP-1RA) in Routine Care of Older AdultsDIABETES, 2019, 68Patorno, ElisabettaKim, Dae H.Pawar, AjinkyaSchneeweiss, SebastianGlynn, Robert J.Munshi, MedhaBessette, Lily G.Kim, Seoyoung C.
- [39] Is early use of sodium-glucose cotransporter type 2 inhibitor (SGLT2i) necessary even in diabetic patients without cardiovascular disease: a prospective study regarding the effect of SGLT2i on left ventricular diastolic functionJournal of Cardiovascular Imaging, 2025, 33 (1)Kina JeonShin Yi JangYou-Bin LeeJihoon KimDarae KimSung-A ChangSung-Ji ParkSang-Chol LeeSeung Woo ParkMoon-Kyu LeeEun Kyoung KimKyu Yeon Hur
- [40] The Association between High Out-of-Pocket Costs and Incidence of Treatment Intensification with an SGLT2 Inhibitor (SGLT2i) or GLP-1 Agonist (GLP-1a) in Patients with Type 2 Diabetes and Established Cardiovascular Disease: A Retrospective Cohort StudyDIABETES, 2022, 71Luo, JingFeldman, RobertRothenberger, Scott D.Hernandez, InmaculadaKorytkowski, Mary T.Gellad, Walid F.